Neurosense Therapeutics Stock Debt To Equity
| NRSN Stock | USD 0.86 0.07 7.53% |
Neurosense Therapeutics fundamentals help investors to digest information that contributes to Neurosense Therapeutics' financial success or failures. It also enables traders to predict the movement of Neurosense Stock. The fundamental analysis module provides a way to measure Neurosense Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Neurosense Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Debt To Equity | 0.02 | 0.02 |
Neurosense | Debt To Equity |
Neurosense Therapeutics Company Debt To Equity Analysis
Neurosense Therapeutics' Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Current Neurosense Therapeutics Debt To Equity | 0.02 % |
Most of Neurosense Therapeutics' fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Neurosense Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Neurosense Debt To Equity Driver Correlations
Understanding the fundamental principles of building solid financial models for Neurosense Therapeutics is extremely important. It helps to project a fair market value of Neurosense Stock properly, considering its historical fundamentals such as Debt To Equity. Since Neurosense Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Neurosense Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Neurosense Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
| Competition |
Neurosense Total Stockholder Equity
Total Stockholder Equity |
|
According to the company disclosure, Neurosense Therapeutics has a Debt To Equity of 0.019%. This is 99.96% lower than that of the Biotechnology sector and 99.9% lower than that of the Health Care industry. The debt to equity for all United States stocks is 99.96% higher than that of the company.
Neurosense Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Neurosense Therapeutics' direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Neurosense Therapeutics could also be used in its relative valuation, which is a method of valuing Neurosense Therapeutics by comparing valuation metrics of similar companies.Neurosense Therapeutics is currently under evaluation in debt to equity category among its peers.
Neurosense Fundamentals
| Return On Equity | -4.95 | ||||
| Return On Asset | -1.51 | ||||
| Current Valuation | 18.72 M | ||||
| Shares Outstanding | 23.13 M | ||||
| Shares Owned By Insiders | 35.03 % | ||||
| Shares Owned By Institutions | 1.08 % | ||||
| Number Of Shares Shorted | 324.35 K | ||||
| Price To Book | 4.15 X | ||||
| EBITDA | (10.63 M) | ||||
| Net Income | (11.28 M) | ||||
| Cash And Equivalents | 10.37 M | ||||
| Cash Per Share | 0.89 X | ||||
| Total Debt | 142 K | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 15.09 X | ||||
| Book Value Per Share | (0.09) X | ||||
| Cash Flow From Operations | (8.45 M) | ||||
| Short Ratio | 2.01 X | ||||
| Earnings Per Share | (0.65) X | ||||
| Target Price | 5.25 | ||||
| Number Of Employees | 18 | ||||
| Beta | 1.57 | ||||
| Market Capitalization | 19.89 M | ||||
| Total Asset | 3.18 M | ||||
| Retained Earnings | (32.07 M) | ||||
| Working Capital | (543 K) | ||||
| Net Asset | 3.18 M |
About Neurosense Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Neurosense Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Neurosense Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Neurosense Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Neurosense Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Neurosense Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Neurosense Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Neurosense Stock
Moving against Neurosense Stock
| 0.75 | DYAI | Dyadic International | PairCorr |
| 0.55 | ESPR | Esperion Therapeutics | PairCorr |
| 0.55 | BMY | Bristol Myers Squibb | PairCorr |
| 0.36 | DNA | Ginkgo Bioworks Holdings | PairCorr |
| 0.33 | FLGC | Flora Growth Corp | PairCorr |
The ability to find closely correlated positions to Neurosense Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Neurosense Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Neurosense Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Neurosense Therapeutics to buy it.
The correlation of Neurosense Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Neurosense Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Neurosense Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Neurosense Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Neurosense Therapeutics Piotroski F Score and Neurosense Therapeutics Altman Z Score analysis. To learn how to invest in Neurosense Stock, please use our How to Invest in Neurosense Therapeutics guide.You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurosense Therapeutics. If investors know Neurosense will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurosense Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.65) | Return On Assets (1.51) | Return On Equity (4.95) |
The market value of Neurosense Therapeutics is measured differently than its book value, which is the value of Neurosense that is recorded on the company's balance sheet. Investors also form their own opinion of Neurosense Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Neurosense Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurosense Therapeutics' market value can be influenced by many factors that don't directly affect Neurosense Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neurosense Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurosense Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurosense Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.